Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib in Advanced or Metastatic Cholangiocarcinoma
NCT02609958Phase 2Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of varlitinib in cholangiocarcinoma (CCA), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Objective Response Rate at 3 years. Started Nov 2015; status: completed.
02
Drugs
varlitinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02609958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609958.